Future Perspectives

Opportunities and challenges in the field of systemic amyloidosis can be grouped into 4 categories. First, a deeper understanding of the pathogenesis of the disease is required. Second, a greater awareness of the disease, which will lead to an earlier diagnosis, is imperative. Third, end points for...

Descripción completa

Detalles Bibliográficos
Autores principales: Dispenzieri, Angela, Merlini, Giampaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576440/
https://www.ncbi.nlm.nih.gov/pubmed/33099434
http://dx.doi.org/10.1016/j.hoc.2020.08.009
_version_ 1783598019649732608
author Dispenzieri, Angela
Merlini, Giampaolo
author_facet Dispenzieri, Angela
Merlini, Giampaolo
author_sort Dispenzieri, Angela
collection PubMed
description Opportunities and challenges in the field of systemic amyloidosis can be grouped into 4 categories. First, a deeper understanding of the pathogenesis of the disease is required. Second, a greater awareness of the disease, which will lead to an earlier diagnosis, is imperative. Third, end points for interventional trials are required to convey us to our fourth aspirations, which are novel therapies for patients with light chain amyloidosis.
format Online
Article
Text
id pubmed-7576440
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-75764402020-10-21 Future Perspectives Dispenzieri, Angela Merlini, Giampaolo Hematol Oncol Clin North Am Article Opportunities and challenges in the field of systemic amyloidosis can be grouped into 4 categories. First, a deeper understanding of the pathogenesis of the disease is required. Second, a greater awareness of the disease, which will lead to an earlier diagnosis, is imperative. Third, end points for interventional trials are required to convey us to our fourth aspirations, which are novel therapies for patients with light chain amyloidosis. Elsevier Inc. 2020-12 2020-10-21 /pmc/articles/PMC7576440/ /pubmed/33099434 http://dx.doi.org/10.1016/j.hoc.2020.08.009 Text en © 2020 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Dispenzieri, Angela
Merlini, Giampaolo
Future Perspectives
title Future Perspectives
title_full Future Perspectives
title_fullStr Future Perspectives
title_full_unstemmed Future Perspectives
title_short Future Perspectives
title_sort future perspectives
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576440/
https://www.ncbi.nlm.nih.gov/pubmed/33099434
http://dx.doi.org/10.1016/j.hoc.2020.08.009
work_keys_str_mv AT dispenzieriangela futureperspectives
AT merlinigiampaolo futureperspectives

Ejemplares similares